Sugi Predict

Sugi Predict / Compounds / SCHEMBL7188665

SCHEMBL7188665

SCHEMBL7188665

Cc1cc(C)c(C(=O)[P](=O)c2ccccc2C(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ KCNK3 O14649 2/20 0.37
▸ KCNK9 Q9NPC2 2/20 0.37
▸ LMNA P02545 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ TAS2R14 Q9NYV8 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ ALOX12 P18054 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ RORC P51449 3/20 0.33
▸ RECQL P46063 1/20 0.33
▸ PTGS1 P23219 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7186793 0.96 KCNK3 (0.37) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL7180621 0.91 TAS2R14 (0.38) CYP3A4KCNK3KCNK9LMNATAS2R14
SCHEMBL7730584 0.88 TAS2R14 (0.37) CYP3A4KCNK3KCNK9LMNASMN1; SMN2
SCHEMBL7175306 0.88 TAS2R14 (0.39) CYP3A4KCNK3KCNK9LMNATAS2R14
SCHEMBL7187550 0.87 TAS2R14 (0.38) CYP3A4KCNK3KCNK9LMNASMN1; SMN2
SCHEMBL7180933 0.87 TAS2R14 (0.39) CYP3A4KCNK3KCNK9LMNASMN1; SMN2
SCHEMBL7181426 0.85 TAS2R14 (0.41) CYP3A4CYP2C19KCNK3KCNK9LMNA
SCHEMBL7180500 0.85 KMT2A (0.39) MEN1KMT2ACYP3A4KCNK3KCNK9
SCHEMBL7183573 0.85 KMT2A (0.39) MEN1KMT2ACYP3A4KCNK3KCNK9
SCHEMBL7180491 0.84 TAS2R14 (0.39) CYP3A4KCNK3KCNK9LMNATAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MEN1 2312/4885KMT2A 1586/4885CYP1A2 1595/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MEN1 2263/4885KMT2A 956/4885CYP1A2 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.